PF-Atlas › Клинические испытания › NCT00256555
Growth Hormone Treatment Study in Children With Cystic Fibrosis
Nutropin AQ · Фаза 2
ID реестра
NCT00256555
Фаза
Фаза 2
Статус
Отозвано
Препарат / вмешательство
Nutropin AQ
Спонсор
University of Texas Southwestern Medical Center
Начало
2000-02
Об исследовании
Cystic fibrosis (CF) is a catabolic condition, and children affected with this disease frequently have problems with growth, despite adequate nutrition. We hypothesize that the anabolic effects of growth hormone (GH) will improve the height and weight of CF patients and thereby improve their clinical status and their quality of life. We further hypothesize that these effects will be sustained for at least one year after GH treatment is complete.
Связанные материалы
Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT00256555 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.